Prognostic factors in patients receiving neoadjuvant 5-fluorouracil plus cisplatin for advanced esophageal cancer (JCOG9907)

Tomoya Yokota, Nobutoshi Ando, Hiroyasu Igaki, Masayuki Shinoda, Ken Kato, Junki Mizusawa, Hiroshi Katayama, Kenichi Nakamura, Haruhiko Fukuda, Yuukou Kitagawa

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective: Neoadjuvant chemotherapy with 5-fluorouracil plus cisplatin and subsequent esophagectomy with two- to three-field lymphadenectomy is a standard treatment for patients with clinical stage II/III squamous cell carcinoma (SCC) of the esophagus. This study investigates the prognostic factors for patients who received neoadjuvant chemotherapy. Methods: Of 164 patients assigned to receive neoadjuvant chemotherapy in the JCOG9907 trial, multivariate analyses were performed for 159 and 149 patients to evaluate the preoperative and the combined preoperative and postoperative prognostic factors, respectively. Results: The multivariate analyses using preoperative factors showed that clinical stage T3 [vs. cT1-2; hazard ratio (HR) 3.60, p = 0.0007] and serum albumin (Alb)

Original languageEnglish
Pages (from-to)143-151
Number of pages9
JournalOncology (Switzerland)
Volume89
Issue number3
DOIs
Publication statusPublished - 2015 Aug 21

    Fingerprint

Keywords

  • Clinical T stage
  • Esophageal squamous cell carcinoma
  • Neoadjuvant chemotherapy
  • Pathological findings
  • Prognostic factors
  • Serum albumin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Yokota, T., Ando, N., Igaki, H., Shinoda, M., Kato, K., Mizusawa, J., Katayama, H., Nakamura, K., Fukuda, H., & Kitagawa, Y. (2015). Prognostic factors in patients receiving neoadjuvant 5-fluorouracil plus cisplatin for advanced esophageal cancer (JCOG9907). Oncology (Switzerland), 89(3), 143-151. https://doi.org/10.1159/000381065